Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NH302
- Development stage
- Phase 1
- Lead developer
- Jiangsu Nhwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Parenteral
01
Overview
NH302 is a peripherally selective kappa-type opioid receptor agonist developed by Beijing Enhua Pharmaceutical Research Institute, a subsidiary of Enhua Pharmaceutical. It is being developed as a Class 1 innovative chemical drug for the treatment of acute pain. Preclinical studies have demonstrated that NH302 exhibits potent agonistic activity at the kappa-type opioid receptor, showing excellent analgesic efficacy across multiple animal models of pain with a low effective dose, long duration of action, and a wide safety margin for sedation. In August 2026, the National Medical Products Administration (NMPA) of China approved the clinical trial application for NH302 injection to initiate Phase 1 clinical trials for acute pain.
- Other names
- NH302 injectionNH-302 injectionNH 302 injectionNH302注射液
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on NH302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NH302.